308 related articles for article (PubMed ID: 16207172)
41. 5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals.
Ishida T; Hamano A; Koiwa T; Watanabe T
Retrovirology; 2006 Oct; 3():69. PubMed ID: 17034647
[TBL] [Abstract][Full Text] [Related]
42. Hide-and-seek: the challenge of viral persistence in HIV-1 infection.
Geeraert L; Kraus G; Pomerantz RJ
Annu Rev Med; 2008; 59():487-501. PubMed ID: 17845138
[TBL] [Abstract][Full Text] [Related]
43. The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency.
De Crignis E; Mahmoudi T
Int Rev Cell Mol Biol; 2017; 328():197-252. PubMed ID: 28069134
[TBL] [Abstract][Full Text] [Related]
44. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
[TBL] [Abstract][Full Text] [Related]
45. HIV-1 latency and eradication of long-term viral reservoirs.
Coiras M; Lopez-Huertas MR; Alcami J
Discov Med; 2010 Mar; 9(46):185-91. PubMed ID: 20350483
[TBL] [Abstract][Full Text] [Related]
46. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
[TBL] [Abstract][Full Text] [Related]
47. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
[TBL] [Abstract][Full Text] [Related]
48. A unified concept of HIV latency.
Bagasra O
Expert Opin Biol Ther; 2006 Nov; 6(11):1135-49. PubMed ID: 17049012
[TBL] [Abstract][Full Text] [Related]
49. Disruption of polycomb repressor complex-mediated gene silencing reactivates HIV-1 provirus in latently infected cells.
Yoon CH; Jang DH; Kim KC; Park SY; Kim HY; Kim SS; Chi SG; Choi BS
Intervirology; 2014; 57(2):116-20. PubMed ID: 24642637
[TBL] [Abstract][Full Text] [Related]
50. Control of HIV-1 RNA load after HAART interruption: relationship with CCR5 co-receptor density and proviral DNA load in HIV-infected patients.
Soriano-Sarabia N; Vallejo A; Fernández G; Genebat M; Gutiérrez S; Muñoz-Fernández MA; Leal M
J Clin Virol; 2007 Sep; 40(1):64-7. PubMed ID: 17662650
[TBL] [Abstract][Full Text] [Related]
51. StpC-based gene therapy targeting latent reservoirs of HIV-1.
Turner LS; Tsygankov AY; Henderson EE
Antiviral Res; 2006 Dec; 72(3):233-41. PubMed ID: 16891001
[TBL] [Abstract][Full Text] [Related]
52. Pinpointing recurrent proviral integration sites in new models for latent HIV-1 infection.
Lange UC; Bialek JK; Walther T; Hauber J
Virus Res; 2018 Apr; 249():69-75. PubMed ID: 29550509
[TBL] [Abstract][Full Text] [Related]
53. Barriers for HIV Cure: The Latent Reservoir.
Castro-Gonzalez S; Colomer-Lluch M; Serra-Moreno R
AIDS Res Hum Retroviruses; 2018 Sep; 34(9):739-759. PubMed ID: 30056745
[TBL] [Abstract][Full Text] [Related]
54. 1st International Workshop on HIV Persistence during Therapy. St. Martin, December 10-12, 2003.
Tossing G
Eur J Med Res; 2004 Feb; 9(2):83-6. PubMed ID: 15090294
[TBL] [Abstract][Full Text] [Related]
55. Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection.
Beilke MA; Traina-Dorge VL; Sirois M; Bhuiyan A; Murphy EL; Walls JM; Fagan R; Winsor EL; Kissinger PJ
Clin Infect Dis; 2007 May; 44(9):1229-34. PubMed ID: 17407044
[TBL] [Abstract][Full Text] [Related]
56. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
Zhu W; Lei R; Le Duff Y; Li J; Guo F; Wainberg MA; Liang C
Retrovirology; 2015 Feb; 12():22. PubMed ID: 25808449
[TBL] [Abstract][Full Text] [Related]
57. Molecular mechanisms of HIV latency.
Cary DC; Fujinaga K; Peterlin BM
J Clin Invest; 2016 Feb; 126(2):448-54. PubMed ID: 26731470
[TBL] [Abstract][Full Text] [Related]
58. Treating the latent reservoir of HIV.
Critchfield JM; Deeks SG
AIDS Read; 2004 Sep; 14(9):485-6. PubMed ID: 15457601
[No Abstract] [Full Text] [Related]
59. Treatment interruptions in HIV-infected subjects.
Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
[TBL] [Abstract][Full Text] [Related]
60. HIV-1 latency in actively dividing human T cell lines.
Jeeninga RE; Westerhout EM; van Gerven ML; Berkhout B
Retrovirology; 2008 Apr; 5():37. PubMed ID: 18439275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
